Contemporary treatment of high-risk localized prostate cancer

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin.59(4), 225–249 (2009).
   PubMed Web of Science ®Google Scholar
• Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl Cancer Inst.90(10), 766–771 (1998).
   PubMed Web of Science ®Google Scholar
• Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology58(6), 843–848 (2001).
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Whittington R, Malkowicz SB et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J. Urol.154(1), 131–138 (1995).
   PubMed Web of Science ®Google Scholar
• Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J. Urol.165(1), 119–125 (2001).
   PubMed Web of Science ®Google Scholar
• Syed S, Petrylak DP, Thompson IM. Management of high-risk localized prostate cancer: the integration of local and systemic therapy approaches. Urol. Oncol.21(3), 235–243 (2003).
   PubMed Web of Science ®Google Scholar
• Carroll PR, Lee KL, Fuks ZY. Cancer of the prostate. In: Cancer Principles and Practice of Oncology. DeVita VT, Hellman S, Rosenberg SA (Eds). Lippincott Williams and Wilkins, PA, USA, 1418–1476 (2001).
   Google Scholar
• D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA280(11), 969–974 (1998).
   PubMed Web of Science ®Google Scholar
• Donohue JF, Bianco FJ Jr, Kuroiwa K et al. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J. Urol.176(3), 991–995 (2006).
   PubMed Web of Science ®Google Scholar
• Yossepowitch O, Eggener SE, Bianco FJ Jr et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J. Urol.178(2), 493–499 (2007).
   PubMed Web of Science ®Google Scholar
• Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA281(17), 1591–1597 (1999).
   PubMed Web of Science ®Google Scholar
• Pinto F, Prayer-Galetti T, Gardiman M et al. Clinical and pathological characteristics of patients presenting with biochemical progression after radical retropubic prostatectomy for pathologically organ-confined prostate cancer. Urol. Int.76(3), 202–208 (2006).
   Google Scholar
• Nguyen K, Eltz S, Drouin SJ et al. Oncologic outcome after radical prostatectomy in men with PSA values above 20 ng/ml: a monocentric experience. World J. Urol.27(5), 653–658 (2009).
   Google Scholar
• Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J. Urol.164(1), 101–105 (2000).
   PubMedGoogle Scholar
• Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA294(4), 433–439 (2000).
   Google Scholar
• Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC. Radical prostatectomy for clinical stage T3a disease. Cancer109(7), 1273–1278 (2007).
   PubMed Web of Science ®Google Scholar
• Magheli A, Rais-Bahrami S, Peck HJ et al. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy. J. Urol.178(4 Pt 1), 1311–1315 (2007).
   PubMedGoogle Scholar
• Tsivian M, Sun L, Mouraviev V et al. Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology74(5), 1090–1093 (2009).
   PubMed Web of Science ®Google Scholar
• Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology DOI:10.1016/j.urology.2009.09.014 (2009) (Epub ahead of print).
   Google Scholar
• Thompson IM Jr, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA296(19), 2329–2335 (2006).
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet366(9485), 572–578 (2005).
   PubMed Web of Science ®Google Scholar
• Wiegel T, Bottke D, Steiner U et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96–02/AUO AP 09/95. J. Clin. Oncol.27(18), 2924–2930 (2009).
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J. Urol.181(3), 956–962 (2009).
   PubMed Web of Science ®Google Scholar
• Walsh PC. Urological oncology: prostate cancer. J. Urol.182(4), 1385–1387 (2009).
   Google Scholar
• Swindle P, Eastham JA, Ohori M et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J. Urol.174(3), 903–907 (2005).
   PubMed Web of Science ®Google Scholar
• MacDonald OK, D’Amico AV, Sadetsky N, Shrieve DC, Carroll PR. Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: from the CaPSURE database. Urol. Oncol.26(3), 271–275 (2008).
   Google Scholar
• Wiegel T, Lohm G, Bottke D et al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome – results of a retrospective study. Int. J. Radiat. Oncol. Biol. Phys.73(4), 1009–1016 (2009).
   PubMed Web of Science ®Google Scholar
• Trock BJ, Han M, Freedland SJ et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA299(23), 2760–2769 (2008).
   PubMed Web of Science ®Google Scholar
• Parker C, Clarke N, Logue J et al. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery). Clin. Oncol. (R. Coll. Radiol.)19(3), 167–171 (2007).
   PubMed Web of Science ®Google Scholar
• Blackard CE. The Veterans’ Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review. Cancer Chemother. Rep.59(1), 225–227 (1975).
   PubMedGoogle Scholar
• Dalkin BL, Ahmann FR, Nagle R, Johnson CS. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J. Urol.155(4), 1357–1360 (1996).
   PubMed Web of Science ®Google Scholar
• Messing EM, Manola J, Yao J et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol.7(6), 472–479 (2006).
   PubMed Web of Science ®Google Scholar
• Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K. Role of androgen deprivation therapy for node-positive prostate cancer. J. Clin. Oncol.27(1), 100–105 (2009).
   Google Scholar
• McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int.97(2), 247–254 (2006).
   PubMed Web of Science ®Google Scholar
• Fair WR, Betancourt JE. Update on Memorial Sloan–Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer. Mol. Urol.4(3), 241–248 (2000).
   Google Scholar
• AUS G, Abrahamsson P-A, Ahlgren G et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int.90, 561–566 (2002).
   PubMed Web of Science ®Google Scholar
• Yee DS, Lowrance WT, Eastham JA, Maschino AC, Cronin AM, Rabbani F. Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial. BJU Int.105(2), 185–190 (2009).
   Google Scholar
• Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med.337(5), 295–300 (1997).
   PubMed Web of Science ®Google Scholar
• Granfors T, Modig H, Damber J, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. Urology159, 2030–2034 (1998).
   Google Scholar
• Lawton CA, Winter K, Murray K et al. Updated results of the Phase III Radiation Therapy Oncology Group (RTOG) trial 85–31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys.49(4), 937–946 (2001).
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med.351(15), 1513–1520 (2004).
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med.351(15), 1502–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol.26(2), 242–245 (2008).
   PubMed Web of Science ®Google Scholar
• Prayer-Galetti T, Sacco E, Pagano F et al. Long-term follow-up of a neoadjuvant chemohormonal taxane-based Phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int.100(2), 274–280 (2007).
   PubMed Web of Science ®Google Scholar
• Shepard DR, Dreicer R, Garcia J et al. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. J. Urol.181(4), 1672–1677 (2009).
   PubMedGoogle Scholar
• Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter Phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J. Urol.180(2), 565–570 (2008).
   PubMed Web of Science ®Google Scholar
• Vuky J, Porter C, Isacson C et al. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer115(4), 784–791 (2009).
   PubMed Web of Science ®Google Scholar
• Sella A, Zisman A, Kovel S, Yarom N, Leibovici D, Lindner A. Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. Urology71(2), 323–327 (2008).
   PubMed Web of Science ®Google Scholar
• Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and Leukemia Group B (CALGB) 90203: a randomized Phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology62(Suppl. 1), 55–62 (2003).
   PubMedGoogle Scholar
• Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer106(8), 1708–1714 (2006).
   PubMed Web of Science ®Google Scholar
• Lu-Yao GL, Albertsen PC, Moore DF et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA300(2), 173–181 (2008).
   PubMed Web of Science ®Google Scholar
• Widmark A, Klepp O, Solberg A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised Phase III trial. Lancet373(9660), 301–308 (2009).
   PubMed Web of Science ®Google Scholar
• Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr. Intermittent endocrine therapy for advanced prostate cancer. Cancer58(11), 2546–2550 (1986).
   PubMed Web of Science ®Google Scholar
• Bong GW, Clarke HS Jr, Hancock WC, Keane TE. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology71(6), 1177–1180 (2008).
   PubMed Web of Science ®Google Scholar
• Calais da Silva FE, Bono AV, Whelan P et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised Phase III study of the South European Uroncological Group. Eur. Urol.55(6), 1269–1277 (2009).
   PubMed Web of Science ®Google Scholar